Navigation Links
Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

in the bone marrow. In the United States, more than 50,000 people are living with MM and approximately 20,000 new cases are diagnosed annually.(i) Worldwide, more than 180,000 people are living with MM and approximately 86,000 new cases are diagnosed annually.(ii)

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801 is a targeted alpha-folate inhibitor currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

Forward Looking Statements

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws.  These forward-looking statements include without limitat
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Today DePuy Synthes Companies ... angle plating systems featuring its proprietary variable angle ... screw trajectory to match patient anatomy and fracture ... bone. The systems are being introduced in conjunction ... (AOFAS) and the International Federation of Foot & ...
(Date:9/19/2014)... /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... report firstly reviews the basic information of ... manufacturing technology. The report then explores global ... listing their product specification, capacity, Production value, ...
(Date:9/19/2014)... 19, 2014 Research ... the addition of the "Global Gynecological ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... classified into wide categories based on their ... treatment of different gynecological conditions that affect ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
... March 5, 2012   Synteract , Inc., a full-service contract ... MBA, as senior vice president of sales and marketing and ... president, global project management, to support growth in the company ... Barr, COO Stewart Bieler, and CFO Patrik Jeanmonod on the ...
... Checkpoint Surgical has received the CE mark ... intraoperative neuroprotective stimulator that helps surgeons locate, identify ... to facilitate nerve preservation and repair. ... certification demonstrates that a medical device meets rigorous ...
Cached Medicine Technology:Synteract Expands Executive Roles to Support Growth 2Synteract Expands Executive Roles to Support Growth 3Checkpoint Surgical Receives CE Mark 2
(Date:9/21/2014)... Over the past five years, the patent ... market, thereby cutting into revenue growth for the ... from Industry Canada, the loss of patent protection for ... billion in 2010 and 2012, respectively. “In response to ... hampered revenue growth, many pharmaceutical manufacturers have streamlined their ...
(Date:9/21/2014)... metastasize? Think of Sparta. , Ancient Greek warriors were ... the demands of battle on distant fields. Cancer cells ... a new study revealing previously unknown differences between cancer ... site, and those that travel to other organs. , ... is the primary cause of cancer-related death, understanding how ...
(Date:9/21/2014)... 2014 Hundreds of Risperdal lawsuits ... Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard ... next monthly meeting has been scheduled for October ... “Our Firm is representing a number of plaintiffs ... We are pleased with its continued progress,” says ...
(Date:9/21/2014)... Cheap Hosting USA, one of the leading review websites, ... the best Reseller hosting suppliers in 2014. “It is ... these companies have outperformed their competitors on hosting features, ... the best web hosting at affordable rates,” the site’s ... reseller hosting is a very popular way for webmasters ...
(Date:9/21/2014)... Dallas, TX (PRWEB) September 21, 2014 ... and Chinese Fenofibrate (CAS 49562-28-9) Industry, 2009-2019 ... on Global and Chinese Fenofibrate (CAS 49562-28-9) ... information of Fenofibrate (CAS 49562-28-9) including its ... explores global and China’s top manufacturers of ...
Breaking Medicine News(10 mins):Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Cancer cells adapt energy needs to spread illness to other organs 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4
... According to the U.S. researchers, 80% accuracy in prediction of ... is achieved by a new test that examines the// genetic ... researchers at Duke University in North Carolina report that this ... only a single drug against a particular cancer but also ...
... studies offers good news and bad news for women faced ... ,The good news is that screening mammography does reduce ... mammograms are 15 percent less likely to die of breast ... ,The bad news is that women in a screened population ...
... are at increased risk of burnout, which seems ... depression, reports a study in the// October Journal ... the American College of Occupational and Environmental Medicine ... of the Finnish Institute of Occupational Health, Helsinki ...
... technical university preparing engineers and other professionals, female foeticide ... take up but the Punjab Technical University (PTU) is ... social issues. // ,The campaign by PTU gets ... and Technology (SVIET) at Banur, 25 km from here. ...
... has always been considered as a 'pleasure chemical,' in charge ... extols a person or animal for the continuous activity that ... certain drugs like cocaine and heroin can simply intensify this ... the University of Michigan adds a new twist to dopamine's ...
... Pharmaceuticals Corporation, Zaditor? (ketotifen fumarate ophthalmic solution 0.025%), ... due to allergic conjunctivitis has been endorsed by ... over-the-counter use. Eye allergies affect around 40 million ... to seasonal allergens like pollen and ragweed, or ...
Cached Medicine News:Health News:Genomic tests for better cancer treatment 2Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 2Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 3Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 4Health News:Burnout Explains Link Between Job Strain and Depression 2Health News:Zaditor? - over-the-counter drug for itchy eyes 2
... Design Holds The Lens Securely During ... Blades Keep The Optic From Being ... Over Release Of The Optic.,Wide Jaw ... During Insertion.,Reusable, Autoclaveable, Made In The ...
... Unique In-Line Footplates Are Turned 90 ... The Diamond Blade While Incising Tissue. ,Special ... Blade Depth Penetration.,Pre-Set Blade Extension Settings ... Retraction And Full Extension.,1mm Wide Snub ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Pocket-sized instrument with 2.5X magnification....
Medicine Products: